 NEW YORK, Feb. 18, 2022 PRNewswire -- Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that Evelyn Peelen, Ph.D., Senior Manager Translational Pharmacology at Immunic, will present preclinical data on the potent anti-inflammatory activity of vidofludimus calcium IMU-838, the companys selective oral DHODH inhibitor, at the 17th Congress of European Crohns and Colitis Organization ECCO. 